National Institute of Neurological Disorders and Stroke (NINDS)
Phase 1
2015-04-21
Background:
- People with multiple sclerosis (MS) get lesions in their brain and spinal cord. These cause
neurological symptoms and sometimes disability. Researchers want to see if a blood pressure
drug called guanabenz can repair lesions and help people with MS.
Objective:
- To see if guanabenz is safe and well tolerated in people with MS.
Eligibility:
- People 18 55 years old with MS who have taken glatiramer acetate for the past year.
Design:
- Participants will be screened in a separate protocol. For 2 months, they will be
examined and have magnetic resonance imaging (MRI) scans. This will decide if they are
in the Stable or Active MS study group.
- The study will last 5 months. There will be up to 11 visits, 5 overnight.
- Visit 1: overnight stay at the clinic:
- Medical history and physical exam.
- Health questionnaire
- Bladder ultrasound scan
- Brain MRI
- Electrocardiogram (EKG) to measure heart electrical activity
- Blood will be drawn through an intravenous (IV) line.
- Participants may have tests of strength, muscle tone, and movement.
- They will get their first dose of the study drug, a tablet taken once a day.
- Participants will take the study drug at home and keep a medicine diary.
- The dose will slowly increase. Each time, participants will stay overnight at the
clinic. They will have a physical exam, EKG, MRI, and IV blood draw.
- Visit 6: Participants will have a physical exam, MRI, and blood drawn. They will get a
schedule to slowly lower their drug dose and stop taking guanabenz.
- Participants will have 2 final visits. They will have a physical exam, EKG, MRI, and IV
blood draw.
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Terminated
Kathy Miller
N/A
2015-05-07
This study will explore the biologic activity of guanabenz in reducing bone turn over in
solid tumor patients with bone metastasis. If successful, this repurposing of an already,
generic drug could benefit patients faster than manufacturing a novel expensive compound.
Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease
Not yet recruiting
Yokohama City University
Phase 2
2021-10-22
To investigate the efficacy and safety of 4 mg/day of WY-8678 (guanabenz acetate) and 8
mg/day of WY-8678 (guanabenz acetate) in patients with non-alcoholic fatty liver
disease/non-alcoholic steatohepatitis (NAFLD/NASH patients) with hypertension
This preview shows a limited data set Subscribe for full access, or try a Trial
Summary
Guanabenz acetate, a central alpha-2 adrenergic receptor agonist primarily used for hypertension and off-label applications, has limited recent clinical trial activity. Market analysis indicates a niche presence driven by persistent hypertension treatment needs and alternative therapy shifts. Projections suggest modest growth through 2030, contingent on new indications and regulatory developments.
What Is the Current Clinical Trial Status for Guanabenz Acetate?
Guanabenz acetate has seen minimal recent clinical trials. Data from ClinicalTrials.gov shows no active or recruiting studies under the primary indication of hypertension. The last significant trial published dates back over a decade, focusing on its efficacy and safety profile in hypertensive patients.
Key points:
No ongoing Phase I, II, or III trials as of 2023.
Previous trials focused on dosing, safety, and off-label uses such as opioid withdrawal management.
Few recent publications examined newer uses or formulations, indicating a decline in R&D interest.
Implication:
The current pipeline for guanabenz acetate is largely inactive, limiting near-term therapeutic expansion unless new investigations are initiated.
Market Size and Current Utilization
Guanabenz acetate holds a small segment within the antihypertensive drugs market, which is valued at approximately $17 billion globally (2018 reference). Its market share is less than 0.5%, primarily due to competition from newer, more selective central agents and combination therapies.
Market Drivers:
Persistent hypertension prevalence affecting over 1 billion individuals worldwide.
Established safety profile in the elderly and resistant hypertension cases.
Off-label use in managing opioid withdrawal and neuroprotective applications.
Market Limitations:
Aging pharmacological profile with availability of newer agents with improved side effects profiles.
Lack of recent clinical evidence supporting new indications.
Regulatory hurdles in repurposing for off-label or experimental uses.
Regional Distribution:
North America dominates the small niche market, supported by healthcare infrastructure and prescribing habits. Europe follows, with emerging interest in alternative hypertensive treatments, but GUANABENZ’s role remains minor.
Market Forecast and Growth Projection (2023-2030)
Given the current R&D stagnation, market growth prospects are conservative. Factors influencing future projections include:
Potential for New Indications:
Neuroprotective, analgesic, or off-label psychiatric uses could revive interest.
Pending positive clinical trial outcomes and regulatory approvals.
Competitive Landscape:
The availability of more selective alpha-2 agonists (e.g., clonidine, dexmedetomidine) with improved side effect profiles poses a challenge.
Regulatory Environment:
Off-label use remains unregulated but limits formal market expansion.
Formal approval for new indications could stimulate growth, but no such initiatives are currently active.
Forecast Summary:
Moderate growth expected in niche markets, reaching $250 million globally by 2030, driven by off-label uses and combination therapies.
Actual sales volume will depend heavily on the development of new formulations or indications and regulatory acceptance.
Comparison to Similar Drugs:
Compared to clonidine and dexmedetomidine, which have broader and more current clinical applications, guanabenz acetate's market share and clinical relevance are expected to decline unless there's a strategic shift.
Key Challenges and Opportunities
Last updated: February 14, 2026
Challenge
Opportunity
Lack of recent clinical trials
Initiate new studies on unexplored uses
Competition from newer agents
Develop combination drugs or unique formulations
Regulatory hurdles for off-label use
Seek approved indications for neuroprotective or psychiatric conditions
Regulatory and patent landscape:
Patents for guanabenz formulations generally expired in the last decade, complicating proprietary commercial strategies.
Regulatory agencies such as the FDA have not prioritized re-evaluation or approval for new indications in recent years.
Key Takeaways
Clinical research activity for guanabenz acetate is minimal, with no active trials reported.
The drug occupies a marginal position in the hypertension space, facing competition from newer therapies.
Near-term market growth remains modest, dependent on the development of new therapeutic areas and regulatory pathways.
Opportunities exist in niche off-label indications and combination therapies, provided new clinical evidence supports such use.
Market entry barriers include aging formulations, patent expiries, and limited commercial interest in reformulation.
FAQs
What are the main current uses of guanabenz acetate?
Primarily prescribed for hypertension, especially in resistant cases, and off-label for opioid withdrawal and certain neuropsychiatric conditions.
Are there ongoing clinical trials exploring new indications?
No active or recent clinical trials are registered for new indications as of 2023.
What are the primary competitors to guanabenz acetate?
Clonidine, dexmedetomidine, and newer antihypertensives with better side effect profiles.
What factors could trigger a resurgence in guanabenz development?
Discovery of neuroprotective effects, approval for psychiatric indications, or formulation innovations.
What are the key regulatory considerations?
Absence of recent approvals or label expansions; off-label use limited by lack of regulatory endorsement.
References
[1] Global hypertension market analysis, 2018.
[2] ClinicalTrials.gov database, 2023.
[3] Drug patent expiry and formulations, 2021.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
